Erratum to: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2051-1426
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Erratum to: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma ; volume:5 ; number:1 ; day:28 ; month:9 ; year:2017 ; pages:1-2 ; date:12.2017
Journal for ImmunoTherapy of Cancer ; 5, Heft 1 (28.9.2017), 1-2, 12.2017
- Keyword
-
Krebs
Onkologie
- Creator
-
Kamat, Ashish M.
- Contributor
-
Bellmunt, Joaquim
Galsky, Matthew D.
Konety, Badrinath R.
Lamm, Donald L.
Langham, David
Lee, Cheryl T.
Milowsky, Matthew I.
O’Donnell, Michael A.
O’Donnell, Peter H.
Petrylak, Daniel P.
Sharma, Padmanee
Skinner, Eila C.
Sonpavde, Guru
Taylor, John A.
Abraham, Prasanth
Rosenberg, Jonathan E.
SpringerLink (Online service)
- DOI
-
10.1186/s40425-017-0280-z
- URN
-
urn:nbn:de:1111-201711277396
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:32 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kamat, Ashish M.
- Bellmunt, Joaquim
- Galsky, Matthew D.
- Konety, Badrinath R.
- Lamm, Donald L.
- Langham, David
- Lee, Cheryl T.
- Milowsky, Matthew I.
- O’Donnell, Michael A.
- O’Donnell, Peter H.
- Petrylak, Daniel P.
- Sharma, Padmanee
- Skinner, Eila C.
- Sonpavde, Guru
- Taylor, John A.
- Abraham, Prasanth
- Rosenberg, Jonathan E.
- SpringerLink (Online service)
Other Objects (12)
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia
An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
Biomarkers for immunotherapy in bladder cancer: a moving target
CSACI position statement: prescribing sublingual immunotherapy tablets for aeroallergens
Urease-powered nanomotor containing STING agonist for bladder cancer immunotherapy
Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition)
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia
An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
Biomarkers for immunotherapy in bladder cancer: a moving target
CSACI position statement: prescribing sublingual immunotherapy tablets for aeroallergens
Urease-powered nanomotor containing STING agonist for bladder cancer immunotherapy
Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition)
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia
An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
Biomarkers for immunotherapy in bladder cancer: a moving target
CSACI position statement: prescribing sublingual immunotherapy tablets for aeroallergens
Urease-powered nanomotor containing STING agonist for bladder cancer immunotherapy